AKRO
Akero Therapeutics Inc

2,288
Loading...
Loading...
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
63

Frequently Asked Questions

What is Market Cap of Akero Therapeutics Inc?
What is the 52-week high for Akero Therapeutics Inc?
What is the 52-week low for Akero Therapeutics Inc?
What is Akero Therapeutics Inc stock price today?
What was Akero Therapeutics Inc stock price yesterday?
What is the PE ratio of Akero Therapeutics Inc?
What is the Price-to-Book ratio of Akero Therapeutics Inc?
What is the 50-day moving average of Akero Therapeutics Inc?
How many employess does Akero Therapeutics Inc has?

Latest AKRO News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.